BASF's First-quarter Sales Reached 23.1 Billion Euros, Up 19% Year-on-year
According to the quarterly report released by BASF Group on April 29, sales in the first quarter of 2022 increased by 3.7 billion euros compared with the first quarter of last year, reaching 23.1 billion euros, a year-on-year increase of 19%. The increase in sales was mainly driven by higher prices, especially in the Chemicals and Materials businesses. Favorable currency factors in each business area also contributed to the sales performance. A slight decrease in overall sales was partially offset. Higher volumes in the Agricultural Solutions, Industrial Solutions, Materials, Nutrition & Care and Chemicals business areas were not able to fully offset the decline in the Surface Technology business areas.
EBIT before special items was EUR 2.8 billion, an increase of EUR 497 million, mainly due to significant earnings growth in the Chemicals segment. EBIT before special items also increased significantly in the Industrial Solutions, Materials and Nutrition & Care business areas. EBIT before special items in the Agricultural Solutions business area improved slightly. Earnings before interest and tax excluding special items in the surface treatment technology business area decreased significantly, mainly due to the impact of the decline in market demand in the automotive industry.
EBIT increased by EUR 474 million compared to the same period in the first quarter of 2021 to EUR 2.8 billion. Net income was 1.2 billion euros, compared with 1.7 billion euros in the same period last year. This was due to an impairment charge recognised by Wintershall Dea, for which BASF included a special charge of around EUR 1.1 billion in its net income proportional to its shareholding (72.7%). The impairments were triggered by the Ukrainian war and related political fallout and, in addition to the Nord Stream 2 loan, also involved assets located in Russia as well as those of the gas transportation business.
Cash flow from operating activities was negative 290 million euros, an increase of 235 million euros compared to the same period last year. Although the proportion of cash used in net working capital has increased due to the increase in input costs and the sharp increase in sales, the improvement in operating performance is still the main reason for the increase in cash flow. Free cash flow improved by EUR 88 million to a negative EUR 893 million.
The BASF Group’s forecast for sales and earnings for fiscal 2022 remains unchanged, with sales expected to be between EUR 74 billion and EUR 77 billion, and EBIT before special items between EUR 6.6 billion and EUR 7.2 billion. Return on capital employed (ROCE) is expected to be between 11.4% and 12.6%, with full-year 2022 carbon dioxide emissions to be between 19.6 million and 20.6 million tons.
2026-07-31
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
First New UV Filter in Nearly 27 Years: BASF's Tinosorb® S Approved by FDA, Marking a Historic Shift for the U.S. Sunscreen Market
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
The Crop Protection Patent Cliff Is Here
-
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
-
EU Clears Carlyle's Acquisition of BASF's Coatings Business, but Demands Divestment of Nouryon's Polysulfide Assets: What Are the Underlying Risks?
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
BASF’s €8.7 Billion Zhanjiang Verbund Site Fully Operational
-
BASF and Hannong Chemical Joint Venture Nonionic Surfactant Plant Begins Operation in South Korea
Recommend Reading
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Evonik Converts Epoxy Hardener Production to 100% Renewable Electricity
-
Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
Strong Cost Support Drives PTA Prices Higher in January
-
MTBE market prices slightly increase in China
-
This Week's PVC Market Shows Narrow Range Fluctuations (1.12-16)
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
January Maleic Anhydride Prices Overall Increased in China